Vir Biotechnology appoints David Liu as chief medical officer

Vir Biotechnology (VIR) announced Wednesday the appointment of David Liu as executive vice president and chief medical officer, effective October 12, 2026. The company said that Liu will be ...

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 ...
citybiz

Vir Biotechnology Names David Liu Chief Medical Officer

Vir Biotechnology Inc. has appointed David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, bringing more than... Read More ...
The Brighterside of News on MSN

Scientists use generative AI to build better proteins for editing DNA

A genome search and protein language model produced new DNA-moving proteins, including one that doubled targeted insertion in lab tests.
tradersunion

Vir Biotechnology appoints David Liu as executive vice president and chief medical officer

Vir Biotechnology appoints David Liu as EVP and CMO, leveraging his immuno-oncology and regulatory expertise for upcoming ...
PE Hub

Altaris completes carve-out of Clarivate’s life sciences and healthcare business

The business provides AI-enabled data intelligence and decision-support tools for R&D and commercialization to the ...
RTTNews

Phase 1, 2, And 3 Clinical Trials Explained: What Every Biotech Investor Needs To Know

Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2 ...
NC Biotech

Alamance Community College receives $474,878 NSF grant for biopharma degree

Alamance Community College (ACC) received a $474,878 grant from the National Science Foundation's Advanced Technological Education program to launch BioQuest, a project that will train students for ...
BioPharma Dive

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...

I believe sake is a form of 'monozukuri' that connects AI, biotechnology, and space. Reflections on a day spent at a GSE2026 side event

The intensity of deep tech felt in UmekitaOn October 7th, I attended 'CONNECT—CO-creating New Change Together—,' a side event ...
NC Biotech

Raleigh-based Vogenx launches IPO, raises $81.3M for metabolic disease drug development

Vogenx Inc. celebrated its Nasdaq debut with an Opening Bell ceremony in August after pricing its IPO at $13 per share, at the high end of its expected range. The company began trading on the Nasdaq ...